Business Context and Reporting Period
The source filing is for Venus Acquisition Corporation, not Microalgo Inc. It is an unaudited Form 10-Q for the three months ended March 31, 2021, filed May 17, 2021. Venus is a Cayman Islands blank-check company formed to pursue a business combination, with an intended focus on businesses connected to the Asian market. It had not commenced operating activities or generated revenue as of March 31, 2021.
The company completed its initial public offering on February 11, 2021, selling 4.6 million units for gross proceeds of $46.0 million, and sold 225,000 private-placement units for $2.25 million.
Financial Results and Position
| Metric | Three months ended March 31, 2021 | Prior comparable period |
|---|---|---|
| Revenue | $0 | $0 |
| Net loss | $108,323 | $7,355 |
| Basic and diluted loss per share | $0.03 loss | $0.01 loss |
| Cash flow used in operations | $198,502 | $6,988 |
| Cash and investments held in trust | $46,460,382 | $0 |
| Cash outside the trust account | $211,814 | $239 |
- Net loss consisted primarily of $78,705 of formation, general and administrative expenses and a $30,000 loss from the change in fair value of warrant liabilities, partially offset by $382 of interest income.
- Operating margins are not meaningful because the company has no operating revenue and is pre-business combination.
- Total assets were $46.8 million, including $46.46 million invested in U.S. Treasury securities in the trust account.
- Total liabilities were $7.6 million, including $6.45 million of warrant liabilities and $1.15 million of deferred underwriting compensation. There was no outstanding related-party advance or promissory note at quarter-end, and the filing reports no long-term debt.
- Shareholders’ equity was $5.0 million. Separately, 3,381,687 ordinary shares subject to possible redemption were classified as temporary equity at $34.16 million.
- Financing activities provided $46.87 million, primarily from the IPO and private placement, while $46.46 million was deposited into the trust account.
Material Changes Versus the Prior Comparable Period
- The company moved from a pre-IPO formation stage to a publicly traded SPAC following the February 2021 IPO.
- Cash increased from $239 to $211,814, while trust-account investments increased from zero to $46.46 million.
- Net loss increased to $108,323 from $7,355, reflecting higher public-company, offering-related and administrative activity.
- Warrant liabilities were newly recognized at $6.45 million and generated a $30,000 non-cash fair-value loss during the quarter.
- Operating cash use increased to $198,502 from $6,988.
Guidance, Outlook, Risks and Unusual Items
- Management expects no operating revenue until completion of a business combination and expects expenses to increase as public-company compliance and due-diligence activities expand.
- The company must complete a business combination by February 11, 2022, subject to up to nine one-month extensions, each requiring a sponsor loan of $153,333 to the trust account, for a potential aggregate of $1.38 million.
- If no business combination is completed within the permitted period, the company expects to redeem the public shares and liquidate. Public rights and warrants may expire worthless.
- Substantially all IPO proceeds are restricted to the trust account and intended for a business combination. Available cash outside the trust account was $211,814, and management stated it does not currently expect to need additional funding, although additional capital could become necessary.
- The sponsor provides administrative services for $10,000 per month beginning February 8, 2021 until the earlier of a business combination or liquidation.
- On May 17, 2021, management concluded that previously issued March 4, 2021 balance-sheet information should not be relied upon because of a misapplication of warrant-accounting guidance. Disclosure controls were deemed ineffective. The filing states that the correction was non-cash and did not affect cash, cash equivalents or total assets.
- COVID-19 could adversely affect the company’s financial position, operations or target search, although the specific impact was not determinable.
- The filing identifies increased cost and reduced availability of directors’ and officers’ liability insurance as a potential impediment to completing a business combination.
- The company had no legal proceedings and no material recognizable subsequent events reported through issuance of the financial statements.
Most Important Facts for Investors to Verify
- Verify the issuer identity: the supplied filing names Venus Acquisition Corporation, while the request metadata names Microalgo Inc.
- Confirm the final warrant classification, valuation methodology and any related restatements or amended filings.
- Assess the deadline, extension mechanics and probability of completing a qualifying business combination before liquidation.
- Review the trust-account protections, redemption terms, sponsor indemnification and restrictions on use of trust funds.
- Reconcile the reported share counts, including 6.05 million ordinary shares outstanding, 3.38 million redeemable shares, rights for up to 482,500 shares and warrants for up to 2.41 million shares.
- Evaluate whether $211,814 of unrestricted cash is sufficient for ongoing expenses and whether sponsor or other working-capital financing may be required.